TL1A: A Key Emerging Pathway in Inflammatory

JAN 8th 2026

2:00 pm CET

CLICK HERE TO REGISTER

Inflammatory bowel disease (IBD) remains a complex and heterogeneous disorder in which chronic intestinal inflammation results from a multifactorial interplay of genetic susceptibility, environmental factors, and immune dysregulation. Despite major therapeutic progress, a considerable proportion of patients continue to experience suboptimal response, loss of efficacy, or disease progression, underscoring the need for innovative and mechanistically targeted treatment approaches. Among the pathways currently under investigation, TL1A has emerged as a key mediator of mucosal inflammation and fibrosis. Acting through its receptor DR3, TL1A amplifies T-cell activation, promotes Th1/Th17 polarization, and enhances pro-inflammatory cytokine cascades. Preclinical and early clinical data suggest that selective blockade of the TL1A/DR3 axis may attenuate inflammation, reduce fibrotic remodeling, and offer a novel therapeutic strategy across both ulcerative colitis and Crohn's disease.

5 min
Introduction
Laurent Peyrin-Biroulet - Silvio Danese

15 min
TL1A: a key emerging pathway in intestinal inflammation
Silvio Danese

15 min
TL1a in UC: where we stand
Laurent Peyrin-Biroulet

15 min
TL1A in CD: emerging opportunities
Vipul Jairath

10 min
Discussion
Laurent Peyrin-Biroulet - Silvio Danese - Vipul Jairath

Silvio DANESE
Director, Gastroenterology and Digestive Endoscopy Unit, IRCCS San Raffaele Hospital; Full Professor of Gastroenterology, Vita-Salute San Raffaele University, Milan Italy

Laurent PEYRIN-BIROULET
Full Professor of Medicine IBD Unit Department of Gastroenterology Nancy University Hospital, France

Vipul JAIRATH
Professor of Medicine Departments of Medicine & Epidemiology and Biostatistics, Division of Gastroenterology, Western University, Canada

Roche